David Joyce


  • The University of Western Australia (M500), 35 Stirling Highway,

    6009 Perth


Calculated based on number of publications stored in Pure and citations from Scopus
If you made any changes in Pure these will be visible here soon.

Personal profile


Prof. David Joyce heads Clinical Pharmacology research in the Pharmacology unit at UWA, with specific research interests in clinical pharmacokinetics in the context of therapeutic drug monitoring and the pharmacological control of macrophage function in inflammatory and neoplastic diseases.
Prof. Joyce is director of the Clinical Pharmacology & Toxicology laboratory at PathWest Laboratory Medicine,  practices clinically in the areas of general internal medicine and clinical pharmacology at Sir Charles Gairdner Hospital and consults in forensic toxicology.
Prof. Joyce also coordinates undergraduate medical teaching in pharmacology and therapeutics at UWA.

Roles and responsibilities

Undergraduate teaching in medicine, science, dentistry
Postgraduate supervision
Clinical Practice

Funding overview

G. K. Rangan, D.A. Joyce. Regulation of tubular epithelial cell proliferation and cyclin D1 by NF-kB/Rel in proteinuric chronic renal diseases. ($35,000). Medical Research Foundation of WA. 2001
M-H Zheng, DA Joyce, Langdon W et al. Large Equipment Grant: BMG Polarstar Optima Microplate Fluorimeter/Luminometer ($82,045). University of WA Permanent Endowment for Medical Research. 2003
J. Xu, D.A. Joyce. Inhibition of RANKL-induced osteoclastogenesis through modulation of NF-кB signalling by PKC isoforms and parthenolide ($20,000). Arthritis Foundation of Western Australia. 2005
G. K. Rangan, D.A. Joyce, JH Steer. Regulation of tubular epithelial cell proliferation and cyclin D1 by NF-kB/Rel in proteinuric chronic renal diseases. ($10,000). Fremantle Hospital Medical Research Foundation. 2002
D.A. Joyce, J.H. Steer. Rac-ROS-NF-kB Pathways in Survival and Growth of Fibroblasts and Macrophages in Chronic Inflammatory Synovial Disease ($10,000). Sir Charles Gairdner Hospital Research Foundation. 2002
DA Joyce; PJ Henry. Macrophage uncoupling protein-2 regulation and expression in inflammatory joint disease and hyperoxic lung damage ($259,250). National Health & Medical Research Council. 2009 -2011
S Ching, C Newbound, DA Joyce, J Beilby. The development of improved pharmacogenomic reporting of thiopurine methyl transferase (TPMT) enzyme activity and genotypes. ($13,500). PathWest QEII Research Grant. 2009 -2010

S Schug, DA Joyce, JJ Inglis. Osteoarthritis pain: Mechanisms and mediators. The roles of NGF and IL-1 ($59,480). Australian and New Zealand College of Anaesthetists. Faculty of Pain Medicine. 2014- 2015.

D Purtill, D Pepperall, J Cooney, DA Joyce. Clinical and laboratory characterisation of endothelial toxicity in patients undergoing conditioning for allogeneic haematopoietic stem cell transplantation ($20,000). Cancer and Palliative Care Network, Health Dept of WA. 2015 -2016.

N Forrest, DA Joyce. Optimising antibiotic (piperacillin/ tazobactam) therapy in pleural infection and cystic fibrosis using a newly developed antibiotic assay ($46,005). North Metropolitan Health Service Research Advisory Council. 2016 -2017.

W.  Lim, DA Joyce, G Wong, A Teixeira-Pinto, PL Thompson. Safety, tolerability and effect on inflammatory marker of colchicine in kidney transplant recipients ($37,017). Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee. 2017 -2018.

G.  MacQuillan, DA Joyce, S O'Halloran, D White. Ethanol abstinence compliance optimisation using measurements of erythrocyte phosphatidylethanol ($27,047). Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee. 2019 -2020.

Teaching overview

Undergraduate & Postgraduate courses: IMED2002; IMED3003; IMED3004: PHAR2210; PHAR2220; PHAR3320; PHAR3320; PHAR1101


Clinical pharmacokinetics in the context of therapeutic drug monitoring; Pharmacology of macrophage regulation in inflammatory and neoplastic disease.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Medicine, MD, D-Penicillamine metabolism in rheumatoid arthritis, University of New South Wales

Award Date: 22 Feb 1988

Medicine, MBBS, The University of Western Australia

Award Date: 1 Dec 1975

External positions

Director, Clinical Pharmacology & Toxicology Laboratory, PathWest Laboratory Medicine WA

15 Jul 2005 → …

Physician, Clinical Pharmacology & General Internal Medicine, Sir Charles Gairdner Hospital

1 Jan 1987 → …

Research expertise keywords

  • Clinical pharmacology
  • Pharmacology of inflammatory cell differentiation and survival intracellular signalling


Dive into the research topics where David Joyce is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or